Ablative Technologies for Urologic Cancers

Gino J. Vricella, Lee E. Ponsky, Jeffrey A Cadeddu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Driven by patient preference and a more favorable oncologic prognosis at diagnosis, there has been a paradigm shift in the treatment of urologic cancers. Although the standard of care for most urologic malignancies continues to be surgical extirpation, ablation, in the form of needle-based or extracorporeal approaches, is quickly establishing itself as a viable primary treatment option. If there is anything to be learned from pioneering studies, it is that there must be strict adherence to inclusion criteria for patient enrollment and that there are real limitations with each approach. It is only with this awareness that we can achieve maximal benefit while limiting the number of unnecessary complications and poor oncologic outcomes.

Original languageEnglish (US)
Pages (from-to)163-178
Number of pages16
JournalUrologic Clinics of North America
Volume36
Issue number2
DOIs
StatePublished - May 2009

Fingerprint

Urologic Neoplasms
Technology
Patient Preference
Standard of Care
Needles
Therapeutics
Neoplasms

Keywords

  • Ablation
  • Cryotherapy
  • Percutaneous
  • Prostate cancer
  • Radiofrequency
  • Radiosurgery
  • Renal tumors

ASJC Scopus subject areas

  • Urology

Cite this

Ablative Technologies for Urologic Cancers. / Vricella, Gino J.; Ponsky, Lee E.; Cadeddu, Jeffrey A.

In: Urologic Clinics of North America, Vol. 36, No. 2, 05.2009, p. 163-178.

Research output: Contribution to journalArticle

Vricella, Gino J. ; Ponsky, Lee E. ; Cadeddu, Jeffrey A. / Ablative Technologies for Urologic Cancers. In: Urologic Clinics of North America. 2009 ; Vol. 36, No. 2. pp. 163-178.
@article{514206c1bb1741f791bbc5a2db27127a,
title = "Ablative Technologies for Urologic Cancers",
abstract = "Driven by patient preference and a more favorable oncologic prognosis at diagnosis, there has been a paradigm shift in the treatment of urologic cancers. Although the standard of care for most urologic malignancies continues to be surgical extirpation, ablation, in the form of needle-based or extracorporeal approaches, is quickly establishing itself as a viable primary treatment option. If there is anything to be learned from pioneering studies, it is that there must be strict adherence to inclusion criteria for patient enrollment and that there are real limitations with each approach. It is only with this awareness that we can achieve maximal benefit while limiting the number of unnecessary complications and poor oncologic outcomes.",
keywords = "Ablation, Cryotherapy, Percutaneous, Prostate cancer, Radiofrequency, Radiosurgery, Renal tumors",
author = "Vricella, {Gino J.} and Ponsky, {Lee E.} and Cadeddu, {Jeffrey A}",
year = "2009",
month = "5",
doi = "10.1016/j.ucl.2009.02.003",
language = "English (US)",
volume = "36",
pages = "163--178",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Ablative Technologies for Urologic Cancers

AU - Vricella, Gino J.

AU - Ponsky, Lee E.

AU - Cadeddu, Jeffrey A

PY - 2009/5

Y1 - 2009/5

N2 - Driven by patient preference and a more favorable oncologic prognosis at diagnosis, there has been a paradigm shift in the treatment of urologic cancers. Although the standard of care for most urologic malignancies continues to be surgical extirpation, ablation, in the form of needle-based or extracorporeal approaches, is quickly establishing itself as a viable primary treatment option. If there is anything to be learned from pioneering studies, it is that there must be strict adherence to inclusion criteria for patient enrollment and that there are real limitations with each approach. It is only with this awareness that we can achieve maximal benefit while limiting the number of unnecessary complications and poor oncologic outcomes.

AB - Driven by patient preference and a more favorable oncologic prognosis at diagnosis, there has been a paradigm shift in the treatment of urologic cancers. Although the standard of care for most urologic malignancies continues to be surgical extirpation, ablation, in the form of needle-based or extracorporeal approaches, is quickly establishing itself as a viable primary treatment option. If there is anything to be learned from pioneering studies, it is that there must be strict adherence to inclusion criteria for patient enrollment and that there are real limitations with each approach. It is only with this awareness that we can achieve maximal benefit while limiting the number of unnecessary complications and poor oncologic outcomes.

KW - Ablation

KW - Cryotherapy

KW - Percutaneous

KW - Prostate cancer

KW - Radiofrequency

KW - Radiosurgery

KW - Renal tumors

UR - http://www.scopus.com/inward/record.url?scp=65249136475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249136475&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2009.02.003

DO - 10.1016/j.ucl.2009.02.003

M3 - Article

VL - 36

SP - 163

EP - 178

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -